A New Species of Mnioes (Hymenoptera: Ichneumonidae) from the United States

This is the first record of the genus Mnioes in the United States. Previously described species are all Neotropic. Townes described the genus in 1946, placing Lampronota? jircunda Cresson, 1874, and Meniscus ? orbitalis Cresson, 1874, in it. The new species described here has been collected from several areas in the United States. This study was made while the author was a graduate student at The University of Michigan, Ann Arbor, Michigan

Cosmic Ray Antiprotons

Cosmic ray antiprotons have been detected for over 20 years and are now measured reliably. Standard particle and astrophysics predict a conventional spectrum and abundance of secondary antiprotons consistent with all current measurements. These measurements place limits on exotic Galactic antiproton sources and non-standard antiproton properties. Complications arise, particularly at low energies, with heliospheric modulation of cosmic ray fluxes and production of standard secondaries from A > 1 nuclear targets. Future experiments and theoretical developments are discussed.Comment: 18 pages, 8 .eps figures, 2 tables; extended/revised contribution to PASCOS99 Symposium; includes World Scientific ws-p8-50x6-00.cls macr

Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance

Lost in the cacophony surrounding the debate about high drug prices is the fundamental principle that pharmaceutical innovation will not occur without the prospect of outsized returns enabled through market exclusivity. Biopharmaceutical patents are currently under siege, subject to challenge both in inter partes review (“IPR”) proceedings and in Hatch-Waxman actions. These twin assaults threaten to eliminate the incentives necessary for biotechnological innovation—particularly for discoveries made upstream in the innovation pipeline—thus imperiling the development of new drug therapies. But a fascinating solution has emerged: invoking tribal immunity to shield pharmaceutical patents from IPR before the Patent Trial and Appeal Board (“PTAB”). This serves two critically important objectives: promoting tribal self-sufficiency, and encouraging investment in life-saving and life-improving new drugs. Contractual partnerships between Native American tribes and pharmaceutical companies not only provide the tribes with a steady stream of royalty revenue, but also insulate biopharmaceutical patents from challenge in IPR proceedings through the invocation of long-established principles of tribal sovereign immunity. This Note is the first piece of scholarship to comprehensively analyze, and advocate for, the right to invoke tribal sovereign immunity in IPR proceedings